PLOD3 Antibody

What is PLOD3 and what cellular functions does it perform?

PLOD3 (procollagen-lysine, 2-oxoglutarate 5-dioxygenase 3) is a multifunctional enzyme involved in collagen biosynthesis. It catalyzes the hydroxylation of lysyl residues and O-glycosylation of hydroxylysyl residues, producing either monosaccharide (Gal) or disaccharide (Glc-Gal) derivatives . These post-translational modifications are crucial for proper collagen structure and function, particularly in highly glycosylated type IV and VI collagens. PLOD3 plays significant roles in fibrosis, tissue remodeling, and has been implicated in various cancer types, including colorectal cancer, lung cancer, and glioma .

What applications are PLOD3 antibodies typically used for in research?

PLOD3 antibodies are versatile tools in molecular biology research with multiple validated applications:

These antibodies have been successfully used to detect PLOD3 in various cell lines including A549, HepG2, HeLa, and PC-3 cells, as well as in human tissues such as placenta and pancreatic cancer tissue .

How should PLOD3 antibodies be stored and handled to maintain optimal performance?

For optimal performance, PLOD3 antibodies should be stored at -20°C where they remain stable for approximately one year after shipment. The antibodies are typically supplied in PBS buffer containing either 0.02% sodium azide and 50% glycerol (pH 7.3) or 0.1% sodium azide and 50% glycerol (pH 7.3), depending on the manufacturer . Aliquoting is generally unnecessary for -20°C storage. Some formulations may contain 0.1% BSA as a stabilizer. When working with the antibody, avoid repeated freeze-thaw cycles which can degrade antibody performance.

What is the molecular weight of PLOD3 and how does this affect antibody detection?

PLOD3 has a calculated molecular weight of 85 kDa (738 amino acids), with the observed molecular weight in Western blot applications typically falling between 80-85 kDa . This slight variation may reflect post-translational modifications or tissue/cell-specific processing. When designing experiments, researchers should anticipate detecting bands within this range and consider the possibility of potential isoforms or modified versions of the protein that may appear at different molecular weights.

What antigen retrieval methods are recommended for PLOD3 immunohistochemistry?

For optimal PLOD3 detection in IHC applications, antigen retrieval with TE buffer at pH 9.0 is recommended as the primary method. Alternatively, citrate buffer at pH 6.0 can be used if the primary method proves suboptimal . This methodological consideration is particularly important when working with formalin-fixed, paraffin-embedded tissues where protein cross-linking can mask epitopes. In published studies examining PLOD3 in colorectal cancer tissues, researchers constructed tissue microarrays with 1.5-mm cores and incubated slides at 60°C for 4 hours, followed by deparaffinization in xylene and rehydration in alcohol before heating in citrate buffer for 23 minutes .

How can researchers validate PLOD3 antibody specificity in their experimental systems?

To ensure antibody specificity, researchers should employ multiple validation approaches:

• Positive and negative controls: Use tissues or cell lines known to express PLOD3 (e.g., A549, HepG2, HeLa) as positive controls and PLOD3 knockdown models as negative controls.

• PLOD3 knockdown validation: Several studies have validated antibody specificity by establishing PLOD3 knockdown cell lines using shRNA or siRNA approaches, which should show reduced or absent signal when probed with the PLOD3 antibody .

• Western blot analysis: Confirm a single band (or expected pattern) at the predicted molecular weight (80-85 kDa).

• Multiple antibody approach: When possible, use antibodies from different vendors or those targeting different epitopes to confirm consistent results.

• Recombinant expression: Compare detection in cells transfected with PLOD3 overexpression vectors versus controls .

What are the recommended dilutions for PLOD3 antibodies in different applications?

The optimal dilution varies by application and specific antibody clone:

Researchers should perform titration experiments in their specific experimental systems to determine optimal conditions, as antibody performance is sample-dependent .

How is PLOD3 expression altered in cancer, and what are the implications for using PLOD3 antibodies in cancer research?

PLOD3 is frequently overexpressed in multiple cancer types compared to normal tissues:

• Colorectal cancer (CRC): PLOD3 is significantly upregulated in CRC tissues compared to adjacent normal tissues at both mRNA and protein levels . High PLOD3 expression correlates with advanced stage disease and poor survival outcomes .

• Lung cancer: PLOD3 overexpression is associated with radioresistance and chemoresistance in lung cancer cells .

• Glioma: PLOD3 overexpression correlates with negative survival outcomes in glioma patients .

These expression patterns make PLOD3 antibodies valuable tools for cancer research, potentially serving as prognostic markers. When designing experiments, researchers should consider tissue-specific expression patterns and ensure appropriate controls are included. For IHC applications in cancer tissues, optimization of staining protocols is crucial, as the microenvironment and tissue architecture may impact antibody performance .

What is the relationship between PLOD3 expression and immune cell infiltration in tumors?

PLOD3 expression shows significant inverse correlation with immune cell infiltration in several cancer types:

• In colorectal cancer, high PLOD3 expression is associated with reduced infiltration of CD8+ T cells, CD4+ T cells, and M1 macrophages .

• PLOD3 expression negatively correlates with immuneScore and StromalScore in CRC, suggesting that tumors with high PLOD3 expression have less immune cell infiltration .

• The infiltration scores of B cell plasma, T cell CD8+, T cell CD4 memory resting, T cell CD4 memory activated, T cell follicular helper, T cell gamma delta, and macrophage M1 were higher in PLOD3-low cohorts than in PLOD3-high cohorts .

When studying the tumor microenvironment, researchers should consider PLOD3's relationship with immune cell markers and potentially perform multiplex immunofluorescence to analyze co-localization patterns .

How can PLOD3 antibodies be used to evaluate potential resistance to cancer immunotherapy?

PLOD3 antibodies can be valuable tools for assessing potential immunotherapy resistance:

• Correlation with immunotherapy response markers: High PLOD3 expression correlates with lower tumor mutation burden (TMB) and microsatellite instability (MSI), both of which are predictive markers for immunotherapy response .

• TIDE score assessment: PLOD3-high tumors show significantly higher TIDE (Tumor Immune Dysfunction and Exclusion) scores, indicating potential resistance to immune checkpoint blockade .

• Validation in immunotherapy-treated cohorts: In one study, non-responders to immunotherapy showed increased PLOD3 expression compared to responders .

• Multiplex analysis: Combining PLOD3 staining with immune checkpoint markers (PD-1, PD-L1) can provide a more comprehensive assessment of the tumor immune microenvironment.

When designing such experiments, researchers should use standardized scoring systems, such as multiplying the strongest intensity score (0=negative, 1=weak, 2=moderate, 3=strong) by the total extensity score (percentage of positive cells: 0=≤5%, 1=5-25%, 2=26-50%, 3=51-75%, 4=≥75%) .

How can researchers use PLOD3 antibodies to investigate the mechanisms underlying PLOD3's role in tumor progression?

PLOD3 antibodies can be employed in multiple advanced techniques to elucidate mechanistic details:

• Co-immunoprecipitation (Co-IP): PLOD3 antibodies have been used successfully in IP applications to identify protein-protein interactions. For example, studies have shown that PLOD3 interacts with TM9SF4 in colorectal cancer and with PKCδ in lung cancer cells .

• ChIP-seq: To investigate transcriptional regulation of PLOD3 and identify potential binding factors.

• Immunofluorescence co-localization: Combine PLOD3 antibodies with markers for subcellular compartments (ER, Golgi) or signaling proteins to understand localization and trafficking.

• Proximity ligation assay (PLA): For detecting and visualizing protein-protein interactions involving PLOD3 in situ.

• Tissue microarray (TMA) analysis: Multiple studies have used PLOD3 antibodies on TMAs to evaluate expression patterns across large cohorts of cancer tissues .

When designing these experiments, researchers should consider using multiple antibody clones and validation approaches to ensure specificity of observed interactions.

What signaling pathways are affected by PLOD3 modulation, and how can antibodies help investigate these mechanisms?

PLOD3 impacts several key signaling pathways that can be investigated using antibodies:

• ERK signaling pathway: PLOD3 silencing inhibits HIF-1α accumulation via the ERK signaling pathway under hypoxia . Researchers can use PLOD3 antibodies alongside phospho-ERK antibodies to examine this relationship.

• TGF-beta signaling in EMT: Gene set enrichment analysis has revealed that genes involved in TGF-beta signaling in epithelial-mesenchymal transition (EMT) are significantly enriched in those positively correlated with PLOD3 . Key genes like TGFB1 and SMURF1 show similar expression patterns to PLOD3.

• p53-independent p21 pathway: PLOD3 silencing induces G1 phase arrest through p53-independent regulation of the p21 pathway . This relationship can be studied using PLOD3 antibodies in combination with cell cycle protein antibodies.

• TNF-α/NF-κB pathway: PLOD3 has been shown to affect the TNF-α/NF-κB pathway in tumor microenvironments .

• Autophagy pathways: PLOD3 interacts with TM9SF4 to promote colorectal cancer progression by enhancing autophagy .

For studying these pathways, researchers should design time-course experiments after PLOD3 modulation (knockdown or overexpression) and use appropriate antibody panels to detect changes in pathway components.

How do methylation changes affect PLOD3 expression, and how can this be studied using antibodies?

Recent research indicates that hypomethylation of the PLOD3 promoter leads to its overexpression in colorectal cancer . To investigate this relationship:

• Combined methylation and expression analysis: Researchers can use PLOD3 antibodies alongside methylation-specific techniques (bisulfite sequencing, methylation-specific PCR) to correlate methylation status with protein expression levels.

• Treatment with demethylating agents: After treating cells with agents like 5-azacytidine, PLOD3 antibodies can be used to assess changes in protein expression via Western blot or IHC.

• ChIP assays: Using antibodies against methylation-related proteins (DNMT1, DNMT3A, DNMT3B) in conjunction with PLOD3 promoter analysis.

• Luciferase reporter assays: Combining methylation site mutations with PLOD3 antibody detection to validate functional effects.

These approaches require careful experimental design, including appropriate controls and validation of methylation status using multiple techniques.

How can PLOD3 antibodies be used to investigate secreted versus intracellular PLOD3 in cancer progression?

Recent studies have shown that PLOD3 can be secreted by colorectal cancer cells and that secreted PLOD3 promotes cancer cell migration and invasion . To investigate this dual function:

• Cell fractionation: Use PLOD3 antibodies to detect the protein in different cellular compartments (cytoplasm, membrane, secretory vesicles).

• Conditioned media analysis: Western blot analysis of conditioned media to detect secreted PLOD3, compared with cellular extracts.

• Immunofluorescence: Combined with markers for secretory pathway components to track PLOD3 trafficking.

• ELISA development: Using PLOD3 antibodies to quantify secreted protein in biological fluids or conditioned media.

• Functional blocking experiments: Using PLOD3 antibodies to neutralize secreted PLOD3 and assess functional outcomes.

When performing these experiments, researchers should consider using antibodies that recognize different epitopes to distinguish potential post-translational modifications that may differ between intracellular and secreted forms.

What are common issues encountered when using PLOD3 antibodies in IHC, and how can they be resolved?

Common issues and their solutions include:

• High background staining:

  • Increase antibody dilution (try 1:200-1:400 for polyclonal antibodies)

  • Optimize blocking conditions (3% BSA for 30 minutes has been effective)

  • Reduce incubation time with secondary antibody

  • Ensure sufficient washing steps (minimum 3 washes with PBS)

• Weak or no signal:

  • Optimize antigen retrieval (try TE buffer pH 9.0 as the primary method)

  • Decrease antibody dilution (try 1:100 for polyclonal antibodies)

  • Extend primary antibody incubation (overnight at 4°C has shown good results)

  • Ensure tissue fixation was appropriate (overfixation can mask epitopes)

• Non-specific staining:

  • Validate antibody specificity using PLOD3 knockdown controls

  • Use tissue-matched controls (known positive and negative)

  • Consider different antibody clones if persistent issues occur

• Inconsistent staining across tissue sections:

  • Standardize tissue processing and fixation protocols

  • Use automated staining platforms when possible

  • Implement tissue microarray approaches for comparative studies

How should researchers quantify and interpret PLOD3 staining patterns in tissue samples?

For accurate quantification and interpretation of PLOD3 staining:

• Standardized scoring system: Implement a scoring system that accounts for both staining intensity and extensity:

  • Intensity: 0=negative, 1=weak, 2=moderate, 3=strong

  • Extensity (percentage of positive cells): 0=≤5%, 1=5-25%, 2=26-50%, 3=51-75%, 4=≥75%

  • Calculate final IHC score by multiplying intensity by extensity scores (maximum value of 12)

• Blind assessment: Have two independent investigators evaluate staining, blind to clinical outcome and clinicopathological data.

• Digital image analysis: Consider using software-based quantification for more objective assessment.

• Subcellular localization: Note whether PLOD3 staining is cytoplasmic, membranous, or nuclear, as this may have functional implications.

• Comparative analysis: Always include normal tissue controls on the same slide to assess relative expression levels.

• Correlation with clinical parameters: Analyze PLOD3 expression in relation to clinicopathological features (tumor stage, grade, survival) to determine prognostic value .

What controls should be included when using PLOD3 antibodies in cancer research studies?

Comprehensive control systems for PLOD3 antibody-based experiments should include:

• Positive tissue controls: Include tissues known to express PLOD3 (placenta tissue, pancreatic cancer tissue) .

• Cell line controls: Include cell lines with confirmed PLOD3 expression (A549, HepG2, HeLa, PC-3) .

• Negative controls:

  • Omit primary antibody but include all other steps

  • Use isotype-matched control antibodies

  • Include PLOD3 knockdown/knockout samples when available

• Gradient expression controls: When possible, include samples with known varying levels of PLOD3 expression.

• Antibody validation controls:

  • Pre-absorption with immunizing peptide

  • Use of multiple antibodies targeting different epitopes

  • Western blot confirmation of specificity at the expected molecular weight (80-85 kDa)

• Technical controls:

  • Tissue processing controls to ensure consistent fixation and processing

  • Staining controls processed in parallel across multiple experimental batches